Product/Composition:- | Itraconazole Capsules |
---|---|
Strength:- | 100 mg |
Form:- | Oral Capsules |
Reference Brands:- | Sporanox(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Itraconazole inhibits fungal cytochrome P450 enzyme 14α-demethylase, disrupting ergosterol synthesis and fungal cell membrane formation. It effectively treats a broad range of fungal infections, including systemic and dermatophyte infections. Benefits include oral administration, good tissue penetration, broad-spectrum activity, and a favorable safety profile for managing fungal diseases.
Itraconazole capsules are approved in the EU and US for treating fungal infections. In the EU, Janssen’s Sporanox and generics are regulated by EMA, backed by comprehensive dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, the FDA approved Sporanox and generic versions based on detailed clinical data, biosimilarity assessments, and ongoing pharmacovigilance. Both regions require robust regulatory dossiers for initial approval and continued safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz, your trusted partner in regulatory solutions, helping facilitate timely market access for itraconazole capsules.